Cargando…

A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics

Ferroptosis, an emerging type of cell death found in the past decades, features specifically lipid peroxidation during the cell death process commonly by iron accumulation. Unfortunately, however, the direct delivery of iron species may trigger undesired detrimental effects such as anaphylactic reac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chenyao, Liu, Zhonglong, Chen, Zhixin, Xu, Deliang, Chen, Lisong, Lin, Han, Shi, Jianlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457667/
https://www.ncbi.nlm.nih.gov/pubmed/34550744
http://dx.doi.org/10.1126/sciadv.abj8833
_version_ 1784571149673299968
author Wu, Chenyao
Liu, Zhonglong
Chen, Zhixin
Xu, Deliang
Chen, Lisong
Lin, Han
Shi, Jianlin
author_facet Wu, Chenyao
Liu, Zhonglong
Chen, Zhixin
Xu, Deliang
Chen, Lisong
Lin, Han
Shi, Jianlin
author_sort Wu, Chenyao
collection PubMed
description Ferroptosis, an emerging type of cell death found in the past decades, features specifically lipid peroxidation during the cell death process commonly by iron accumulation. Unfortunately, however, the direct delivery of iron species may trigger undesired detrimental effects such as anaphylactic reactions in normal tissues. Up to date, reports on the cellular ferroptosis by using nonferrous metal elements can be rarely found. In this work, we propose a nonferrous ferroptosis-like strategy based on hybrid CoMoO(4)-phosphomolybdic acid nanosheet (CPMNS)–enabled lipid peroxide (LOOH) accumulation via accelerated Mo(V)-Mo(VI) transition, elevated GSH depletion for GPX4 enzyme deactivation, and ROS burst, for efficient ferroptosis and chemotherapy. Both in vitro and in vivo outcomes demonstrate the notable anticancer ferroptosis efficacy, suggesting the high feasibility of this CPMNS-enabled ferroptosis-like therapeutic concept. It is highly expected that such ferroptosis-like design in nanocatalytic medicine would be beneficial to future advances in the field of cancer-therapeutic regimens.
format Online
Article
Text
id pubmed-8457667
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-84576672021-10-01 A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics Wu, Chenyao Liu, Zhonglong Chen, Zhixin Xu, Deliang Chen, Lisong Lin, Han Shi, Jianlin Sci Adv Biomedicine and Life Sciences Ferroptosis, an emerging type of cell death found in the past decades, features specifically lipid peroxidation during the cell death process commonly by iron accumulation. Unfortunately, however, the direct delivery of iron species may trigger undesired detrimental effects such as anaphylactic reactions in normal tissues. Up to date, reports on the cellular ferroptosis by using nonferrous metal elements can be rarely found. In this work, we propose a nonferrous ferroptosis-like strategy based on hybrid CoMoO(4)-phosphomolybdic acid nanosheet (CPMNS)–enabled lipid peroxide (LOOH) accumulation via accelerated Mo(V)-Mo(VI) transition, elevated GSH depletion for GPX4 enzyme deactivation, and ROS burst, for efficient ferroptosis and chemotherapy. Both in vitro and in vivo outcomes demonstrate the notable anticancer ferroptosis efficacy, suggesting the high feasibility of this CPMNS-enabled ferroptosis-like therapeutic concept. It is highly expected that such ferroptosis-like design in nanocatalytic medicine would be beneficial to future advances in the field of cancer-therapeutic regimens. American Association for the Advancement of Science 2021-09-22 /pmc/articles/PMC8457667/ /pubmed/34550744 http://dx.doi.org/10.1126/sciadv.abj8833 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Wu, Chenyao
Liu, Zhonglong
Chen, Zhixin
Xu, Deliang
Chen, Lisong
Lin, Han
Shi, Jianlin
A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
title A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
title_full A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
title_fullStr A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
title_full_unstemmed A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
title_short A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
title_sort nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457667/
https://www.ncbi.nlm.nih.gov/pubmed/34550744
http://dx.doi.org/10.1126/sciadv.abj8833
work_keys_str_mv AT wuchenyao anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT liuzhonglong anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT chenzhixin anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT xudeliang anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT chenlisong anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT linhan anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT shijianlin anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT wuchenyao nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT liuzhonglong nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT chenzhixin nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT xudeliang nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT chenlisong nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT linhan nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics
AT shijianlin nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics